BRISTOL MYERS SQUIBB CO (BMY) vs ELI LILLY & Co (LLY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BMY | LLY |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $48.19B | $65.18B |
| Revenue growth (YoY) | ▼ 0.2% | ▲ 44.7% |
| Net income | $7.05B | $20.64B |
| Gross margin | 71.1% | 83.0% |
| Diluted EPS | $3.46 | $22.95 |
| Insider net (6 mo) | +54.4K sh • 3 sells • 0 buys | −37.3K sh • 5 sells • 0 buys |
| Institutional owners | 64 | 72 |
| Institutional value held | $65.66B | $563.64B |
| Next earnings (est.) | Feb 4, 2027 | Around Feb 3, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BRISTOL MYERS SQUIBB CO (BMY)
Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes and sells innovative medicines for patients with serious diseases. Read more →
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 to succeed a drug manufacturing business founded in Indianapolis in 1876, discovers, develops, manufactures, and markets human pharmaceutical products. It operates in a single business segment. Read more →
Source: SEC EDGAR.